

Information Regarding Clinical Trial

| | |
|------------------------------------|--|
| Title | A Phase 2 Study of Abemaciclib in Combination with Pembrolizumab for Patients with Stage IV NSCLC or ER+, HER2- Breast Cancer |
| Protocol Number | I3Y-MC-JPCE |
| Sponsor | Lilly |
| Investigator | J. Thaddeus Beck, MD 3232 N. North Hills Blvd. Fayetteville, AR 72703 |
| Study Related Phone Numbers | 479-587-1700 (24 hours) |
| Key Points for Study | KRAS by local testing, PDL1 by central testing Tx naïve for metastatic Dz must have archived tissue at screening but new Bx preferred Mandatory Bx at C3 CNS mets must be Tx and stable x14 days Measurable disease |